{"organizations": [], "uuid": "2c211b70788d9e91ec0ad55e8bb84c64c2b2804a", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "https://www.reuters.com/finance/markets/us", "section_title": "US Stock Market News - Dow Jones, Nasdaq, S&amp;P 500 | Reuters.com", "url": "https://www.reuters.com/article/brief-amir-efrati-reports-53-percent-sta/brief-amir-efrati-reports-5-3-percent-stake-in-arcturus-therapeutics-idUSFWN1S71A5", "country": "US", "domain_rank": 408, "title": "BRIEF-Amir Efrati Reports 5.3 Percent Stake In Arcturus Therapeutics", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.1, "site_type": "news", "published": "2018-05-01T05:10:00.000+03:00", "replies_count": 0, "uuid": "2c211b70788d9e91ec0ad55e8bb84c64c2b2804a"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-amir-efrati-reports-53-percent-sta/brief-amir-efrati-reports-5-3-percent-stake-in-arcturus-therapeutics-idUSFWN1S71A5", "ord_in_thread": 0, "title": "BRIEF-Amir Efrati Reports 5.3 Percent Stake In Arcturus Therapeutics", "locations": [], "entities": {"persons": [{"name": "amir efrati", "sentiment": "none"}, {"name": "efrati", "sentiment": "none"}], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "arcturus therapeutics ltd", "sentiment": "negative"}, {"name": "sec", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 30 (Reuters) - Arcturus Therapeutics Ltd:\n* AMIR EFRATI - ON APRIL 27, SENT LETTER TO ISRAELI COURT SHOWING OPPOSITION TO TRANSACTION THEY BELIEVE ARCTURUS THERAPEUTICS BOARD HAS BEEN PURSUING\n* AMIR EFRATI REPORTS 5.3 PERCENT STAKE IN ARCTURUS THERAPEUTICS AS OF APRIL 27, 2018 - SEC FILING\n* AMIR EFRATI SAYS INTEND TO REVIEW INVESTMENT IN ARCTURUS THERAPEUTICS ON A CONTINUING BASIS\n* AMIR EFRATI SAYS PURCHASED ARCTURUS THERAPEUTICS' SHARES BASED ON BELIEF THAT SHARES, WHEN PURCHASED, WERE UNDERVALUED Source : bit.ly/2jhVcGg Further company coverage: (Reuters.Briefs@thomsonreuters.com)\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://bit.ly/2jhVcGg", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-05-01T05:10:00.000+03:00", "crawled": "2018-05-01T00:22:24.018+03:00", "highlightTitle": ""}